Related Experiment Video
Updated: Dec 18, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Development of a novel insulin receptor (IR) antagonist that exhibits anti-breast tumor activity
Kuang Wenbin1, Liu Xiaoqin2, Deng Qiuchan1
1Department of Laboratory, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong, People's Republic of China.
Abstract:
Many reports have indicated that the insulin receptor (IR) causes tumorigenesis and the development of breast cancer. It has been considered a potential target for treating IR-related tumors. Traditionally, there are two categories of insulin receptor (IR) antagonists, they are small molecule antagonists and anti-IR antibodies. Here, we describe a new method (anti-idiotypic antibody strategy) for the development of IR antagonist. Hybridoma technology was employed to design and identify a series of anti-idiotypic antibodies against insulin. After repeated screening and identification, an anti-idiotypic antibody against IR (AK98) was obtained. Analysis through competitive ELISA and competitive receptor binding indicated that AK98 mimicked the receptor binding epitope of insulin. The interaction between AK98 and IR was determined using indirect immunofluorescence, immunoelectron microscopy, and Immunoprecipitation-Western (IP-WB). Further research using a tumor cell model revealed that AK98 inhibited insulin-IR binding and IR-mediated intracellular signaling pathways. Conclusively, the main purpose of this paper is that we proposed a new method (anti-idiotypic antibody strategy) to develop the insulin receptor (IR) antagonist (AK98), and a series of experiments showed that the anti-idiotypic antibody (AK98) exhibited good antagonistic activity against IR. This work suggests that the anti-idiotypic antibody may be a potential strategy to develop IR antagonists that can be used in treating breast cancer.
Insights
Researchers developed a novel anti-idiotypic antibody (AK98) strategy to create insulin receptor (IR) antagonists. This new approach shows promise for developing treatments for IR-related breast cancer.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The insulin receptor (IR) is implicated in tumorigenesis and breast cancer development.
- IR antagonists are potential therapeutic agents for IR-related tumors.
- Existing IR antagonists include small molecules and anti-IR antibodies.
Purpose of the Study:
- To introduce a novel anti-idiotypic antibody strategy for developing insulin receptor (IR) antagonists.
- To characterize a specific anti-IR antibody, AK98, developed using this strategy.
- To evaluate the potential of AK98 as a therapeutic agent for breast cancer.
Main Methods:
- Hybridoma technology was used to generate anti-idiotypic antibodies against insulin.
- Screening and identification of anti-IR antibody AK98.
- Competitive ELISA, receptor binding assays, indirect immunofluorescence, immunoelectron microscopy, and Immunoprecipitation-Western (IP-WB) were employed to characterize AK98's interaction with IR.
Main Results:
- AK98 was identified as an anti-IR antibody that mimics the insulin receptor binding epitope.
- AK98 demonstrated inhibition of insulin-IR binding and IR-mediated intracellular signaling in a tumor cell model.
- The interaction between AK98 and IR was confirmed through various biochemical and imaging techniques.
Conclusions:
- The anti-idiotypic antibody strategy is a viable method for developing IR antagonists.
- The developed anti-IR antibody, AK98, exhibits significant antagonistic activity against the insulin receptor.
- Anti-idiotypic antibodies like AK98 represent a potential therapeutic strategy for treating breast cancer.
Related Concept Videos
01:28Insulin: The Receptor and Signaling Pathways
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...